Author
Boehringer Ingelheim (Austria)ORCID 0000-0002-2842-4089Unclaimed ORCID profile · follow to get notified of new preprints
3 papers
Recent·Most cited
Rósula García‐Navas, Carmela Gómez, Anabel Clemente-Serrano…·Eugenio Santos
This study shows that combining SOS1 inhibitor BI-3406 with BCR/ABL TKIs like imatinib improves survival and overcomes resistance in CML models.
Fernando C. Baltanás, Maximilian Kramer‐Drauberg, Rósula García‐Navas…·Eugenio Santos
This study shows that the SOS1 inhibitor BI-3406 effectively reduces tumor growth in KRAS mutant cancers, similar to genetic SOS1 ablation, with comparable efficacy to another KRAS inhibitor.
Brianna R. Daley, Nancy E. Sealover, Bridget A. Finniff…·Robert L. Kortum
This study shows that SOS1 inhibition with BI-3406 enhances G12C inhibitor efficacy and delays resistance in lung adenocarcinoma by targeting resistance mechanisms and drug-tolerant persister cells.